19 Jun

Infineon Raises $1.7 Billion in Capital to Fund Its Cypress Deal

WRITTEN BY Sneha Nahata

Infineon raises capital

German chip maker Infineon Technologies has reportedly raised 1.55 billion euros (~$1.74 billion) in capital by selling its shares to fund its acquisition of Cypress Semiconductor (CY). Infineon has sold ~113 million new shares at 13.70 euros each through private placements to institutional investors, according to a statement released on June 18. The transaction will increase its share capital by 10%.

Infineon closed 1.05% higher at 15.65 euros on June 18. Cypress was up 0.7% at $22.18 on the same day. Cypress stock has gained 29.1% year-to-date as of June 18 compared to the S&P 500, which is up nearly 16.1% in the same period.

Deal financing

On June 3, Infineon, a maker of power chips used in cars, server farms, smartphones, and more, agreed to buy US rival Cypress Semiconductor for more than $10 billion (9 billion euros) as it made efforts to expand in the high-growth automotive, industrial, and Internet-of-Things sectors. The deal could help Infineon become the top supplier of automotive chips.

Infineon had planned to buy Cypress, a manufacturer of flash memory chips and microcontrollers, with equity, debt, and cash. Infineon will finance ~30% of the deal’s value with equity and the remainder with debt as well as cash in hand.

Latest articles

On November 14, The George Soros Fund Management LLC filed 13F. The firm's total market value was around $3.6 billion at the end of Q3 2019.

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.